Avivagen Inc. Announces Results for the Second Quarter Ending April 30, 2020
Ottawa, ON /Business Wire/ June 2, 2020 / Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen” or the “Corporation”), a world leader in natural alternatives to antibiotics with its OxC-beta™ technology, announces its unaudited financial results for the second quarter of 2020. For the three-month period ended April 30, 2020, the Corporation reported revenues of $29,625, a decrease …Read More
Avivagen Announces Increase in North American OxC-betaTM Livestock Order Following Successful Dairy Field Tests
Industrias Melder revises initial order from 300 kgs to 2 tonnes Ottawa, ON /Business Wire/ May 20, 2020 / – Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”) a life sciences corporation focused on developing and commercializing immune-system improving products for livestock, companion animal and human applications, is pleased to announce that its North American purchase order for …Read More
Avivagen Announces Results From Its Annual General Meeting April 8, 2020
Ottawa, ON / Business Wire / April 8, 2020 / – Avivagen Inc. (TSXV:VIV) (“Avivagen” or the “Corporation”), announces that at the Corporation’s Annual General Meeting (AGM) held today the Corporation’s shareholders voted to support all of the resolutions that came before the meeting. The resolutions included the reappointment of McGovern Hurley LLP as Avivagen’s auditor …Read More
Avivagen Secures Largest-Yet Order of OxC-beta™ Livestock
Ottawa, ON /Business Wire/ April 07, 2020 / Avivagen Inc. (TSXV:VIV) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhance and support immune function, thereby supporting general health and performance, has received its largest yet order for OxC-beta™ Livestock from UNAHCO, its long-standing …Read More
Avivagen Inc. to Issue Shares to holders of Debentures in lieu of Annual Maintenance Fee
Ottawa, ON /Business Wire/ April 2, 2020/ – Avivagen Inc. (TSXV:VIV) (“Avivagen” or the “Corporation”) announces that a total of 3,752 common shares will be issued at the rate of $0.61 per share to satisfy the maintenance fee of $2,280 owing in respect of the debentures issued on April 9, 2019. Such shares will be …Read More
Avivagen Secures New Sales of OxC-beta™ in Taiwan and Thailand
Ottawa, ON / Business Wire / April 2,2020 / – Avivagen Inc. (TSXV:VIV) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhance and support immune function, thereby supporting general health and performance, has signed two orders to purchase to sell OxC-beta™ in Asia. …Read More
